Rennova Health, Inc. (RNVA)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -234.81 Thousand USD | 97.08% |
| 2021 | -1.26 Million USD | -38.54% |
| 2020 | -8.41 Million USD | 56.29% |
| 2019 | -24.05 Million USD | -123.83% |
| 2018 | -11.78 Million USD | 13.11% |
| 2017 | -26.75 Million USD | 47.9% |
| 2016 | -14.68 Million USD | -6.87% |
| 2015 | -39.55 Million USD | -471.58% |
| 2014 | -5.16 Million USD | -18.73% |
| 2013 | -3.3 Million USD | 14.48% |
| 2012 | -3.87 Million USD | -56.81% |
| 2011 | -2.5 Million USD | -180.13% |
| 2010 | -1.23 Million USD | 92.95% |
| 2009 | -12.77 Million USD | -82.99% |
| 2008 | -6.9 Million USD | 52.47% |
| 2007 | 2.32 Million USD | -21.82% |
| 2006 | -12.37 Million USD | -77.74% |
| 2005 | -7.64 Million USD | 24.54% |
| 2004 | -10.41 Million USD | -51.27% |
| 2003 | -5.74 Million USD | 48.63% |
| 2002 | -11.57 Million USD | -68.87% |
| 2001 | -7.34 Million USD | 51.72% |
| 2000 | -5.86 Million USD | -20.9% |
| 1999 | -11.37 Million USD | 16.19% |
| 1998 | -13.56 Million USD | -154.55% |
| 1997 | -4.32 Million USD | -222.22% |
| 1996 | 5.5 Million USD | -45.78% |
| 1995 | 7.9 Million USD | 315.0% |
| 1994 | 2.4 Million USD | 427.87% |
| 1993 | -610 Thousand USD | -142.07% |
| 1992 | 1.45 Million USD | 806.25% |
| 1991 | 160 Thousand USD | 101.88% |
| 1990 | -8.49 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | 888.92 Thousand USD | -53.89% |
| 2023 Q2 | 2.4 Million USD | 170.97% |
| 2023 Q3 | -262.21 Thousand USD | -110.89% |
| 2022 FY | - USD | 97.08% |
| 2022 Q3 | -677.92 Thousand USD | -318.54% |
| 2022 Q4 | 1.92 Million USD | 384.37% |
| 2022 Q2 | -161.97 Thousand USD | 89.4% |
| 2022 Q1 | -1.52 Million USD | -1322.21% |
| 2021 Q4 | 125.05 Thousand USD | 104.88% |
| 2021 FY | - USD | -38.54% |
| 2021 Q3 | -2.56 Million USD | -485.45% |
| 2021 Q1 | -2.56 Million USD | 62.74% |
| 2021 Q2 | -437.74 Thousand USD | 82.96% |
| 2020 FY | - USD | 56.29% |
| 2020 Q1 | -3.81 Million USD | 38.76% |
| 2020 Q2 | 3.71 Million USD | 197.37% |
| 2020 Q3 | -3.96 Million USD | -206.61% |
| 2020 Q4 | -6.89 Million USD | -74.12% |
| 2019 Q1 | -5.13 Million USD | -42.35% |
| 2019 Q2 | -5.22 Million USD | -1.7% |
| 2019 Q3 | -8.29 Million USD | -58.77% |
| 2019 Q4 | -6.23 Million USD | 24.85% |
| 2019 FY | - USD | -123.83% |
| 2018 FY | - USD | 13.11% |
| 2018 Q1 | -3.36 Million USD | -92.78% |
| 2018 Q4 | -3.6 Million USD | -45.78% |
| 2018 Q3 | -2.47 Million USD | -48.46% |
| 2018 Q2 | -1.66 Million USD | 50.5% |
| 2017 Q2 | -3.15 Million USD | 21.76% |
| 2017 Q3 | -4.19 Million USD | -32.83% |
| 2017 Q4 | -1.74 Million USD | 58.36% |
| 2017 Q1 | -4.03 Million USD | 31.81% |
| 2017 FY | - USD | 47.9% |
| 2016 FY | - USD | -6.87% |
| 2016 Q1 | -6.03 Million USD | 67.55% |
| 2016 Q2 | -4.38 Million USD | 27.31% |
| 2016 Q3 | -8.2 Million USD | -87.03% |
| 2016 Q4 | -5.91 Million USD | 27.9% |
| 2015 Q2 | -1.27 Million USD | -69.64% |
| 2015 Q3 | -907 Thousand USD | 28.81% |
| 2015 FY | - USD | -471.58% |
| 2015 Q1 | -751 Thousand USD | 30.07% |
| 2015 Q4 | -18.6 Million USD | -1950.89% |
| 2014 Q2 | -1.21 Million USD | -30.75% |
| 2014 Q1 | -930 Thousand USD | 3.93% |
| 2014 Q4 | -1.07 Million USD | -9.82% |
| 2014 Q3 | -978 Thousand USD | 19.57% |
| 2014 FY | - USD | -18.73% |
| 2013 Q4 | -968 Thousand USD | -17.05% |
| 2013 Q3 | -827 Thousand USD | -25.3% |
| 2013 Q2 | -660 Thousand USD | 14.62% |
| 2013 Q1 | -773 Thousand USD | 35.96% |
| 2013 FY | - USD | 14.48% |
| 2012 Q1 | -739 Thousand USD | -85.21% |
| 2012 FY | - USD | -56.81% |
| 2012 Q2 | -693 Thousand USD | 6.22% |
| 2012 Q3 | -1.28 Million USD | -85.43% |
| 2012 Q4 | -1.2 Million USD | 6.07% |
| 2011 Q4 | -399 Thousand USD | 27.06% |
| 2011 FY | - USD | -180.13% |
| 2011 Q3 | -547 Thousand USD | 34.65% |
| 2011 Q2 | -837 Thousand USD | -126.4% |
| 2011 Q1 | 3.17 Million USD | 547.88% |
| 2010 Q1 | -269 Thousand USD | 96.57% |
| 2010 Q2 | -2.48 Million USD | -823.05% |
| 2010 Q3 | -881 Thousand USD | 64.52% |
| 2010 Q4 | -708 Thousand USD | 19.64% |
| 2010 FY | - USD | 92.95% |
| 2009 Q1 | -2.66 Million USD | -131.19% |
| 2009 Q4 | -7.83 Million USD | -388.04% |
| 2009 FY | - USD | -82.99% |
| 2009 Q2 | -3.06 Million USD | -14.99% |
| 2009 Q3 | -1.6 Million USD | 47.55% |
| 2008 Q1 | -14.04 Million USD | -1779.43% |
| 2008 FY | - USD | 52.47% |
| 2008 Q3 | -2.18 Million USD | -120.87% |
| 2008 Q4 | -1.15 Million USD | 47.2% |
| 2008 Q2 | -987 Thousand USD | 92.97% |
| 2007 Q2 | -1.87 Million USD | -62.97% |
| 2007 Q1 | -1.15 Million USD | 82.3% |
| 2007 FY | - USD | -21.82% |
| 2007 Q4 | 836 Thousand USD | 110.05% |
| 2007 Q3 | 398 Thousand USD | 121.18% |
| 2006 Q2 | -1.65 Million USD | 10.5% |
| 2006 Q1 | -1.84 Million USD | -904.35% |
| 2006 FY | - USD | -77.74% |
| 2006 Q4 | -6.51 Million USD | -138.35% |
| 2006 Q3 | -2.73 Million USD | -65.24% |
| 2005 Q2 | -1.92 Million USD | 44.76% |
| 2005 FY | - USD | 24.54% |
| 2005 Q1 | -3.48 Million USD | -9.46% |
| 2005 Q4 | -184 Thousand USD | 93.49% |
| 2005 Q3 | -2.82 Million USD | -46.88% |
| 2004 Q2 | -557 Thousand USD | 86.16% |
| 2004 Q3 | -118 Thousand USD | 78.82% |
| 2004 FY | - USD | -51.27% |
| 2004 Q4 | -3.18 Million USD | -2596.61% |
| 2004 Q1 | -4.02 Million USD | -3825.93% |
| 2003 Q4 | -2.08 Million USD | 117.01% |
| 2003 Q2 | -976 Thousand USD | 38.73% |
| 2003 Q1 | -1.54 Million USD | 44.45% |
| 2003 FY | - USD | 48.63% |
| 2003 Q3 | -989 Thousand USD | 38.71% |
| 2002 Q4 | -2.98 Million USD | 28.99% |
| 2002 FY | - USD | -68.87% |
| 2002 Q3 | -4.44 Million USD | -68.51% |
| 2002 Q2 | -2.6 Million USD | -150.64% |
| 2002 Q1 | -1.01 Million USD | 42.1% |
| 2001 Q2 | -2.14 Million USD | 43.94% |
| 2001 Q4 | -2.03 Million USD | 14.86% |
| 2001 Q3 | -2.15 Million USD | -1.63% |
| 2001 Q1 | -3.62 Million USD | 57.73% |
| 2001 FY | - USD | 51.72% |
| 2000 Q3 | 143 Thousand USD | 106.88% |
| 2000 FY | - USD | -20.9% |
| 2000 Q4 | -324 Thousand USD | -6079.02% |
| 2000 Q1 | -1.67 Million USD | 37.15% |
| 2000 Q2 | -2 Million USD | -27.23% |
| 1999 Q1 | -4.6 Million USD | -51.61% |
| 1999 FY | - USD | 16.19% |
| 1999 Q4 | -2.6 Million USD | 31.58% |
| 1999 Q3 | -3.7 Million USD | -2.7% |
| 1999 Q2 | -3.5 Million USD | 21.28% |
| 1998 Q1 | -1.7 Million USD | -81.82% |
| 1998 Q4 | -3.2 Million USD | -6.9% |
| 1998 Q3 | -2.7 Million USD | 9.38% |
| 1998 Q2 | -3 Million USD | -60.0% |
| 1998 FY | - USD | -154.55% |
| 1997 Q2 | -900 Thousand USD | -425.0% |
| 1997 Q3 | -700 Thousand USD | 30.77% |
| 1997 Q4 | -900 Thousand USD | -22.22% |
| 1997 FY | - USD | -222.22% |
| 1997 Q1 | 800 Thousand USD | -50.0% |
| 1996 FY | - USD | -45.78% |
| 1996 Q3 | 900 Thousand USD | -73.08% |
| 1996 Q4 | 1 Million USD | 14.29% |
| 1996 Q1 | 2.2 Million USD | 18.75% |
| 1996 Q2 | 2.8 Million USD | 36.84% |
| 1995 FY | - USD | 315.0% |
| 1995 Q4 | 1.8 Million USD | -88.81% |
| 1995 Q2 | 13.1 Million USD | 141.32% |
| 1995 Q3 | 14.3 Million USD | 9.16% |
| 1995 Q1 | -31.7 Million USD | -378.07% |
| 1994 FY | - USD | 427.87% |
| 1994 Q4 | 11.4 Million USD | -3.96% |
| 1994 Q3 | 11.87 Million USD | 18.7% |
| 1994 Q2 | 10 Million USD | 0.0% |
| 1993 FY | - USD | -142.07% |
| 1992 FY | - USD | 806.25% |
| 1991 FY | - USD | 101.88% |
| 1990 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 79.81% |
| Arrayit Corporation | -3.07 Million USD | 92.37% |
| Atlantic International Corp. | -5.38 Million USD | 95.643% |
| Biocept, Inc. | -30.24 Million USD | 99.224% |
| Bioqual, Inc. | 3.03 Million USD | 107.744% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 68.996% |
| DermTech, Inc. | -97.89 Million USD | 99.76% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.008% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 98.84% |
| iMD Companies, Inc. | -154.65 Thousand USD | -51.828% |
| IDenta Corp. | 71.58 Thousand USD | 428.013% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 106.12% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 706.914% |
| InVitro International | 6680.00 USD | 3615.195% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 95.68% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -1835.182% |
| Medical Imaging Corp. | -896.74 Thousand USD | 73.815% |
| NovelStem International Corp. | -3.78 Million USD | 93.797% |
| Optigenex Inc. | -1.18 Million USD | 80.213% |
| PharmChem, Inc. | 1.05 Million USD | 122.282% |
| Proteome Sciences plc | -1.13 Million USD | 79.348% |
| Response Genetics, Inc | -19.66 Million USD | 98.806% |
| RushNet, Inc. | -614.85 Thousand USD | 61.81% |
| ScreenPro Security Inc. | -3.43 Million USD | 93.164% |
| Stella Diagnostics Inc. | -5.7 Million USD | 95.886% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 97.714% |
| Todos Medical Ltd. | -9.39 Million USD | 97.5% |